4BIO Capital

The Boehringer Ingelheim Venture Fund Mission is to invest in the development of pioneering science – from idea to proof of concept – which offer the potential to provide significant benefits firstly for patients and also for our business. Our Investment PhilosophyActivating success: Our primary aim is to activate success for those companies and entrepreneurs we support and to earn a reputation as a long-term trusted partner. Added-value expertise: Beyond capital investment, we intend to take an active role with our portfolio companies – delivering significant added value through our own extensive drug discovery, scientific and managerial expertise and access to selected relevant experts and knowledge. Nevertheless, we also attach significant importance to confidentiality, establishing ethical walls to protect our portfolio companies and entrepreneurs. Ongoing investment: The Boehringer Ingelheim Venture Fund has an initial commitment of €300 million. Opening investments of up to €3 million per venture will be made at the early stage with subsequent staged investments made to align with each venture’s progress, up to a total of €15 million per venture (up to €7.5 million for Digital Health) over its life. Opportunities for the future: Boehringer Ingelheim would welcome the opportunity to enter into strategic partnerships with those companies in which the Venture Fund has invested. However we will be equally proud to see portfolio companies develop in their own right or enter strategic partnerships with other pharmaceutical partners. Ultimately, our goal is to add value to those companies we invest in, delivering success for them and generating revenues to finance further new investment to benefit patients. Our Investment Focus Therapeutic and Digital Health Focus Our sole focus is to search for significant enhancements in patient care through innovative and pioneering science including (but not limited to): Immunomodulation, esp. Immuno-Oncology Tissue Regeneration, e.g. stem cells, NCEs, biologics New Therapeutic Modalities, e.g. genetherapy, cell-based therapeutics Microbiome, esp. approaches based on NCEs and biologics Antiinfectives with new mechanism of action Patients Care Management, e.g. diagnosis and monitoring of disease, prevention of onset and progression of disease (incl. digital biomarkers), population management Medication adherence Digital companion therapy Digital therapy as stand alone These reflect our interest in platform technologies and the extention of the current therapeutic area focus of Boehringer Ingelheim and demonstrate our commitment to investigate new treatment modalities and technologies, beyond our existing landscape, for the potential future benefit of patients. Geographical Focus We recognise that innovation is not restricted by geography and welcome applications from entrepreneurs worldwide.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

AGP is a fund management company spun out from EDBI, a state-owned fund in Singapore, with former senior employees as founders. The fund will continue to have close affiliation to EDBI providing unique opportunities for collaboration and investments. We are raising a dedicated healthcare fund (“AGP Healthcare Fund” or “AGPHC”) to build on our successes at EDBI and to capture new opportunities. Our partners have a credible reputation built on years of working together at EDBI and having strong domain expertise in healthcare, with extensive network and deep linkages to the Singapore, regional, and global biomedical and healthcare ecosystem. Our investment areas* include medtech & manufacturing, services & others, healthtech, and biotech & therapeutics. At AGP Healthcare Fund, we focus on investing in growth-stage companies (Series C to pre-IPO) (~75%) and venture-stage companies (Series A and B) (~25%). Our unique position in serving both SEA/Asia and global markets is driven by our belief that SEA is an emerging innovation hub with tremendous potential to build differentiated and valuable healthcare companies. We see opportunities for healthcare companies to capitalize on the Asian growth momentum by leveraging Singapore's position as a nexus between the East and the West. With our global insights and proven track record, we provide valuable guidance and advice to founders in expanding their businesses globally. Investment areasMedtech & Mfg, Services & Others: minimally invasive devices, medical equipment manufacturing & distribution, surgical robotics, diagnostics, healthcare services, new modalities CRDMOs, life science equipment & consumables, drug manufacturing & distribution Healthtech: remote patient monitoring, virtual care delivery, digital health platform, workflow automation, healthcare analytics, AI in healthcare imaging, digital therapeutics, chronic disease management Biotech & Therapeutics: cell & gene therapy, RNA therapeutics, AI drug discovery, targeted therapy & immunotherapy, gene editing tools & infrastructure, regenerative medicine & tissue engineering, and life science tools

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

age1 catalyzes contrarian, founder-led companies that will increase healthy human lifespan, yielding the most valuable companies to ever exist. Through our investments, we strive for counterfactual impact. We are creating a future where all people have agency over how long they live in good health. Our vision is to make aging and age-related disease optional for all. Why does it matter? We’re at a historic inflection point in biotech. In the next decade, the preservation of a healthy life will go from a futuristic ideal to an actionable right. In the original draft of The Declaration of Independence, Thomas Jefferson famously wrote that all humans “derive rights inherent and inalienable, among which are the preservation of life, liberty, and the pursuit of happiness.” This is our goal at age1: the preservation of healthy life, to enable a more dignified future globally for humans of all ages. Some of the biggest human accomplishments progressed us towards this goal. Since the inception of antibiotics in the 1910s, they have extended the global life expectancy by 23 years. These now-taken-for-granted solutions combat the propensity of humans to develop infections constituting modern medicine, yet the thought of democratizing such therapeutics was once laughable. Similarly, we foresee a future with universal access to a healthy life enabled by longevity biotech. The preservation of healthy life is critical because it will enable: Reduced suffering: Loss of identity, clarity of mind, physical independence, and grief over the decline of our loved ones are all pains we’ve come to expect as necessary counterparts to life. We strive for a future where this is not the norm. Increased time with family, friends, and yourself: To maintain the ability to spend quality time with family, friends, pets, nature – and yourself – for longer. Diminished financial burden: By 2029, the United States will spend $3 trillion dollars yearly – half its total federal budget– on the medical and social care of adults aged 65 and older. Health, quality of life, and longevity are foundational to global prosperity. The future age1 wants to create Currently, there are zero FDA-approved interventions for aging or longevity. We know of 0 interventions that extend maximum lifespan in humans. And 0 clinical trials are underway to test if a therapeutic can intervene in human aging, holistically. Zero. Most of the field is focused on the “hallmarks of aging”, a useful but reductionist framework that doesn’t address the systematic, multifactorial nature of aging biology. As a result, the field is dogmatic and not growing at the pace it should. We have tunnel-visioned on the same shortlist of mostly small-molecule interventions, candidates like rapamycin and senolytics, without substantive progress in determining exactly how they affect aging in humans. After 45 years of research in the modern era of the field, we only have evidence to rigorously support that lifestyle/exercise and nutrition can extend the average life expectancy in humans. We need to change this current trajectory. Our goal is to: Finally put small molecule interventions to the test in a rigorous way to answer once and for all if they can affect human aging. Push the aging field to embrace newer modalities such as biologics, cell therapy, gene therapy, and tissue engineering to fulfill the promise of regenerative medicine. The future age1 wants to create is one with effective and safe moonshot interventions, approved for human use. We focus on interventions which: Delay: Delay or prevent aging Replace: Replace aged or damaged cells and tissues with youthful ones Restore: Turn the clock back to restore the age of cells and tissues to a youthful stage Pause: Pause the aging clock in human tissues and cells by inducing stasis Build now, age later We must partner with the most ambitious, talented founders and the best LPs in order to tackle one of medicine’s biggest problems. This inflection point in history may never present itself again. In a new letter from Laura, she shares her predictions and why this is the decade to build for the future of longevity. age1 will seed the best founders the field has ever seen, equipping them with the right resources to finally attain proven safe, equitable interventions to delay, restore, replace, and pause aging in humans. With the first-ever FDA-approved longevity drugs from these companies, they’ll scale to obtain $10B+ valuations and impact global health systems. For these founder-led biotechs to succeed and thrive, we need world-class founders, talent, and investors. That’s you. It is only through a collective effort that we can deliver the best returns for our future. Every investment in the aging field – time, effort, and capital – doesn’t just extend the runway of a company or team, but the runway of healthy human life.